The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

Empagliflozin is a potent, selective sodium glucose cotransporter 2 (SGLT2) inhibitor in development as an oral antidiabetic treatment. This QT interval study assessed potential effects of empagliflozin on ventricular repolarisation and other electrocardiogram (ECG) parameters. A randomised, placebo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cardiovascular Diabetology 2013-04, Vol.12 (1), p.70-70
Hauptverfasser:	Ring, Arne, Brand, Tobias, Macha, Sreeraj, Breithaupt-Groegler, Kerstin, Simons, Gudrun, Walter, Beate, Woerle, Hans J, Broedl, Uli C
Format:	Artikel
Sprache:	eng
Schlagworte:	Action Potentials Adolescent Adult Benzhydryl Compounds - adverse effects Benzhydryl Compounds - pharmacokinetics Biometrics Blood pressure Body mass index Cardiac arrhythmia Cardiovascular disease Confidence intervals Cross-Over Studies Diabetes Dosage and administration Double-Blind Method Drug dosages Drug therapy Electrocardiography Epidemiology Family medical history Female Fluoroquinolones - adverse effects Germany Glucosides - adverse effects Glucosides - pharmacokinetics Health aspects Heart Conduction System - drug effects Heart Conduction System - physiopathology Heart rate Heart Rate - drug effects Humans Hypoglycemic agents Hypoglycemic Agents - adverse effects Hypoglycemic Agents - pharmacokinetics Long QT Syndrome - chemically induced Long QT Syndrome - diagnosis Long QT Syndrome - physiopathology Male Middle Aged Mortality Moxifloxacin Original Investigation Plasma Risk Assessment Risk Factors Sodium Sodium-Glucose Transporter 2 - metabolism Sodium-Glucose Transporter 2 Inhibitors Time Factors Type 2 diabetes Ventricular function Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!